| Literature DB >> 32466446 |
Uratcha Sadjapong1, Supachai Yodkeeree2, Somporn Sungkarat3, Penprapa Siviroj1.
Abstract
The efficacy of exercise to reverse frailty in the aging population has not been extensively investigated. This study aimed to investigate the effectiveness of a multicomponent exercise program (MCEP) on frailty, physical performance (handgrip strength, Berg Balance Scale (BBS), Timed Up and Go test (TUG), and VO2Max), blood biomarkers (Interleukin-6 (IL-6) and C-reactive protein (CRP)) in frail older adults. A randomized controlled trial using an allocation concealment method, included 64 older adults (77.78 ± 7.24 years), were divided into two parallel groups using block randomization: an MCEP group (n = 32) and a control group (n = 32). The combined center- and home-based MCEP training consisted of chair aerobic, resistance, and balance, which was carried out 3 days per week for 24 weeks. A mixed model repeated measure ANOVA demonstrated significant interaction effects of group x time for BBS, TUG and frailty scores (p < 0.001). Additionally, the post-hoc analysis revealed that the MCEP group showed significantly improved BBS, TUG, and frailty scores (p < 0.01), at both 12- and 24-weeks. When compared with controls at 12-weeks, the MCEP group decreased IL-6 and CRP levels (p < 0.05). The combined center- and home-based MCEP were effective in reversing frailty to pre-frailty and improving physical performance especially balance in the older population.Entities:
Keywords: balance; biomarkers; frailty; multicomponent exercise; muscle strength; quality of life
Year: 2020 PMID: 32466446 PMCID: PMC7312630 DOI: 10.3390/ijerph17113760
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Flow chart of the study procedure.
Multicomponent exercise program protocol.
| Exercise Training | Description | Duration | Intensity Progression |
|---|---|---|---|
| Chair Aerobic Training | (i) seated marching, (ii) leg marching, (iii) arm swing, (iv) tap and clap, (v) side bend, and (vi) arm raised | 10−20 min | month 1: 10 min |
| Resistance Training with Theraband | (i) arm curl, (ii) backward arm press, (iii) hip flexor, (iv) hip extensor, (v) hip adductor, (vi) hip abductor, (vii) knee flexor, (viii) knee extensor, (ix) ankle plantar flexor, and (x) ankle dorsiflexor | 25−30 min | month 1, Reps: 8 × 2 set, |
| Balance Training | (i) sit to stand, (ii) knee bends, (iii) backwards walking, (iv) walking and turning around, (v) sideways walking, and (vi) heel toe standing (vii) heel toe walking (viii) one leg stand | 10 min | Month 1: two hands support |
Baseline characteristics of participants.
| Characteristics | Control Group | MCEP Group | |
|---|---|---|---|
| Age (y), mean ± SD | 78.87 ± 1.32 | 76.68 ± 1.14 | 0.64 |
| Sex, | |||
| Female | 16 (50.0) | 23 (71.9) | 0.06 |
| Male | 16 (50.0) | 9 (28.1) | |
| Number of Comorbidities, mean ± SD | 1.25 ± 0.76 | 1.09 ± 0.96 | 0.35 |
| Number of Types of Medication, mean ± SD | 2.62 (1.91) | 2.28 ± 1.97 | 0.67 |
| Self-health Rating, | |||
| Excellent | 4 (12.5) | 6 (18.8) | 0.61 |
| Good | 19 (59.4) | 16 (50.0) | |
| Fair / poor | 9 (28.1) | 10 (31.2) | |
| BMI, mean ± SD | 21.28 (0.69) | 21.37 (0.68) | 0.84 |
| HRQOL Score (range, 0−100), mean ± SD | 60.77 (16.84) | 61.45 (13.3) | 0.27 |
| Frailty Score, mean ± SD | 3.25 (0.50) | 3.18 (0.39) | 0.58 |
| Frailty Criteria, | |||
| Weight Loss | 8 (25.0) | 6 (18.8) | 0.76 |
| Low Grip Strength | 31 (96.9) | 29 (90.6) | 0.61 |
| Low Walking Speed | 25 (78.1) | 24 (75) | 1.00 |
| Exhaustion | 15 (46.9) | 17 (53.1) | 0.84 |
| Low Physical Activity | 29 (90.6) | 32 (100.0) | 0.27 |
MCEP = Multicomponent exercise program, BMI = Body Mass Index, HRQOL = Health-related quality of life. Statistical significance at p < 0.05 using Independent Sample t-test for continuous data, and Chi-square test for categorical data.
Comparisons of outcome between groups in physical performance, frailty score and HRQOL at baseline, 12 and 24 weeks.
| Parameters | Control Group ( | MCEP Group ( | Group × Time # | ||||
|---|---|---|---|---|---|---|---|
| Baseline | 12-Weeks | 24-Weeks | Baseline | 12-Weeks | 24-Weeks |
| |
|
| |||||||
| Strength (Handgrip (kg)) | 15.50 ± 6.47 | 16.28 ± 7.00 | 16.70 ± 8.05 | 15.71 ± 6.21 | 19.56 ± 5.27 *,† | 18.84 ± 5.01 † | 0.08 |
| Berg Balance Score | 49.96 ± 4.40 | 45.34 ± 8.65 | 44.46 ± 9.52 † | 49.12 ± 3.58 | 53.12 ± 3.16 *,† | 52.68 ± 3.49 *,† | <0.01 |
| TUG (sec) | 12.43 ± 5.04 | 15.57 ± 7.65 † | 15.75 ± 6.96 † | 12.21 ± 2.26 | 10.48 ± 2.16 *,† | 10.33 ± 2.91 *,† | <0.01 |
| VO2Max | 26.85 ± 4.57 | 26.12 ± 4.60 | 25.92 ± 4.07 | 26.53 ± 3.14 | 28.69 ± 4.39 * | 27.59 ± 4.14 | 0.07 |
|
| 3.25 ± 0.50 | 3.03 ± 1.20 | 3.09 ± 0.92 | 3.18 ± 0.39 | 1.59 ± 0.83 *,† | 1.65 ± 0.86 *,† | <0.01 |
|
| |||||||
| Overall | 61.28 ± 16.17 | 60.49 ± 21.63 | 56.69± 13.34 | 61.90 ± 13.23 | 61.79 ± 20.92 | 59.56 ± 14.00 | 0.58 |
| PCS | 53.56 ± 17.83 | 52.53 ± 20.43 | 52.82 ± 20.98 | 53.38 ± 14.28 | 64.88 ± 22.96 † | 60.78 ± 22.5 | 0.17 |
| MCS | 73.88 ± 17.41 | 70.68 ± 21.94 | 69.36 ± 20.28 | 71.11 ± 15.87 | 74.14 ± 21.79 | 72.81 ± 21.71 | 0.25 |
All data are expressed as means ± SD; # Analysis of two-way repeated-measures ANOVA; * = Significant difference between groups at p < 0.05; † = Significant difference between baseline and post-intervention at p < 0.05; HRQOL = Health Related Quality of Life; SF-36 = 36-Item Short Form Survey; PCS = Physical Component Summary; MCS = Mental Component Summary.
Figure 2Change in physical performance from baseline to the end of the study between the intervention and control groups with interaction effects of group x time as follows: (a) change in strength; (b) change in Borg Balance Score; (c) change in Timed Up and Go test; (d) change in Vo2 Max; and (e) change in frailty score. Values are mean ± standard deviation. * = Significantly different at p < 0.05.
Comparisons of outcome between groups in blood biomarker at baseline and 12 weeks.
| Blood Biomarker | Control Groupleft | MCEP Groupleft | Group × Time # | ||
|---|---|---|---|---|---|
| Baseline | 12-Weeks | Baseline | 12-Weeks |
| |
| IL-6 | 11.93 ± 17.56 | 11.04 ± 8.93 | 10.15 ± 6.25 | 8.16 ± 8.58 † | 0.005 |
| CRP | 3.97± 5.82 | 4.60 ± 6.91 | 3.83 ± 5.13 | 2.49 ± 4.46 † | 0.022 |
All data are expressed as means ± SD; # Analysis of two-way repeated-measures ANOVA. † = Significant difference between baseline and post-intervention at p < 0.05.